Drugs / MARNETEGRAGENE AUTOTEMCEL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03825783 | Apr 2019 → Oct 2021 | leukocyte adhesion deficiency 1 | Rocket Pharmaceuticals Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT03812263 | Aug 2019 → Sep 2023 | leukocyte adhesion deficiency 1 | Rocket Pharmaceuticals Inc. | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MARNETEGRAGENE AUTOTEMCEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802256 ↗ |
| Known as | Ladicell | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802256 ↗ |
| Known as | RP-L201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03812263 ↗ |
| Route | Intravenous | “administered as a single intravenous infusion” NCT03812263 ↗ |
| Target | ITGB2 | “a self-inactivating lentiviral vector carrying the therapeutic ITGB2 gene” NCT03812263 ↗ |